RxDoctor Payments Data

Joshua Balderman, MD

Vascular Surgery · Tucson, AZNPI 1306285325

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (47.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Inari Medical, Inc. accounts for 76.1% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2022 at $57,761 and has fallen 90.8% since, to $5,304 in 2025. Among vascular surgery clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$135,121in general payments, 2019–2025

Across 473 payments — averaging $285.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$103K
  • Medtronic$9K
  • Bard Peripheral Vascular, Inc.$9K
  • Stryker$4K
  • Abbott$3K
  • W. L. Gore & Associates, Inc.$2K
  • plus $6K from 32 others
$218,720in research payments, 2019–2025

Across 47 payments — averaging $4653.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$156K
  • Inari Medical, Inc.$51K
  • Stryker$12K

What the payments were for

  • Consulting fees$64,34648%
  • Speaking & faculty fees$38,32528%
  • Travel & lodging$16,59912%
  • Food & beverage$13,99510%
  • Education$1,8571%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$135,121 in reported general payments places this provider in the 90th percentile of 105 vascular surgery providers in Arizona.

See all vascular surgery providers in Arizona

Medicare billing

Part B allowed, 2024
$419,033
Medicare patients
722
Services billed
2,791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban128$97,048
XareltoRivaroxaban32$34,007
Cilostazol126$3,288
ClopidogrelClopidogrel Bisulfate196$2,266
Atorvastatin Calcium67$1,029
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$53$97,048128 claims
Johnson & JohnsonXarelto$105$34,00732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 105 vascular surgery providers in Arizona.

Other vascular surgery in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →